Angiopoietin-2: An angiopoietin that is closely related to ANGIOPOIETIN-1. It binds to the TIE-2 RECEPTOR without receptor stimulation and antagonizes the effect of ANGIOPOIETIN-1. However its antagonistic effect may be limited to cell receptors that occur within the vasculature. Angiopoietin-2 may therefore play a role in down-regulation of BLOOD VESSEL branching and sprouting.Angiopoietin-1: The first to be discovered member of the angiopoietin family. It may play a role in increasing the sprouting and branching of BLOOD VESSELS. Angiopoietin-1 specifically binds to and stimulates the TIE-2 RECEPTOR. Several isoforms of angiopoietin-1 occur due to ALTERNATIVE SPLICING of its mRNA.Receptor, TIE-2: A TIE receptor tyrosine kinase that is found almost exclusively on ENDOTHELIAL CELLS. It is required for both normal embryonic vascular development (NEOVASCULARIZATION, PHYSIOLOGIC) and tumor angiogenesis (NEOVASCULARIZATION, PATHOLOGIC).Angiopoietins: A family of structurally-related angiogenic proteins of approximately 70 kDa in size. They have high specificity for members of the TIE RECEPTOR FAMILY.Receptor, TIE-1: A TIE receptor found predominantly on ENDOTHELIAL CELLS. It is considered essential for vascular development and can form a heterodimer with the TIE-2 RECEPTOR. The TIE-1 receptor may play a role in regulating BLOOD VESSEL stability and maturation.Receptors, TIE: A family of structurally-related tyrosine kinase receptors that are expressed predominantly in ENDOTHELIAL CELLS and are essential for development of BLOOD VESSELS (NEOVASCULARIZATION, PHYSIOLOGIC). The name derives from the fact that they are tyrosine kinases that contain Ig and EGF domains.Angiogenesis Inducing Agents: Agents that induce or stimulate PHYSIOLOGIC ANGIOGENESIS or PATHOLOGIC ANGIOGENESIS.Vascular Endothelial Growth Factor A: The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.Neovascularization, Physiologic: The development of new BLOOD VESSELS during the restoration of BLOOD CIRCULATION during the healing process.Endothelial Cells: Highly specialized EPITHELIAL CELLS that line the HEART; BLOOD VESSELS; and lymph vessels, forming the ENDOTHELIUM. They are polygonal in shape and joined together by TIGHT JUNCTIONS. The tight junctions allow for variable permeability to specific macromolecules that are transported across the endothelial layer.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Vascular Endothelial Growth Factors: A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.Mycoplasma pulmonis: A species of gram-negative bacteria highly pathogenic to RATS and MICE. It is the primary cause of murine respiratory mycoplasmosis.Angiogenic Proteins: Intercellular signaling peptides and proteins that regulate the proliferation of new blood vessels under normal physiological conditions (ANGIOGENESIS, PHYSIOLOGICAL). Aberrant expression of angiogenic proteins during disease states such as tumorigenesis can also result in PATHOLOGICAL ANGIOGENESIS.Endothelial Growth Factors: These growth factors are soluble mitogens secreted by a variety of organs. The factors are a mixture of two single chain polypeptides which have affinity to heparin. Their molecular weight are organ and species dependent. They have mitogenic and chemotactic effects and can stimulate endothelial cells to grow and synthesize DNA. The factors are related to both the basic and acidic FIBROBLAST GROWTH FACTORS but have different amino acid sequences.Receptor Protein-Tyrosine Kinases: A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.Lymphokines: Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity.Blood Vessels: Any of the tubular vessels conveying the blood (arteries, arterioles, capillaries, venules, and veins).Vascular Endothelial Growth Factor Receptor-2: A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.Pericytes: Unique slender cells with multiple processes extending along the capillary vessel axis and encircling the vascular wall, also called mural cells. Pericytes are imbedded in the BASEMENT MEMBRANE shared with the ENDOTHELIAL CELLS of the vessel. Pericytes are important in maintaining vessel integrity, angiogenesis, and vascular remodeling.Retinal Neovascularization: Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.Membrane Glycoproteins: Glycoproteins found on the membrane or surface of cells.Capillaries: The minute vessels that connect the arterioles and venules.Endothelium, Vascular: Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.Vascular Endothelial Growth Factor Receptor-1: A 180-kDa VEGF receptor found primarily in endothelial cells that is essential for vasculogenesis and vascular maintenance. It is also known as Flt-1 (fms-like tyrosine kinase receptor-1). A soluble, alternatively spliced isoform of the receptor may serve as a binding protein that regulates the availability of various ligands for VEGF receptor binding and signal transduction.Intercellular Signaling Peptides and Proteins: Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal.Retinal Vessels: The blood vessels which supply and drain the RETINA.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Angiogenesis Inhibitors: Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Receptors, Vascular Endothelial Growth Factor: A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.In Situ Hybridization: A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes.Retinal Perforations: Perforations through the whole thickness of the retina including the macula as the result of inflammation, trauma, degeneration, etc. The concept includes retinal breaks, tears, dialyses, and holes.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Capillary Permeability: The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Fovea Centralis: An area approximately 1.5 millimeters in diameter within the macula lutea where the retina thins out greatly because of the oblique shifting of all layers except the pigment epithelium layer. It includes the sloping walls of the fovea (clivus) and contains a few rods in its periphery. In its center (foveola) are the cones most adapted to yield high visual acuity, each cone being connected to only one ganglion cell. (Cline et al., Dictionary of Visual Science, 4th ed)Proteins: Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Up-Regulation: A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Receptors, Growth Factor: Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells.Umbilical Veins: Venous vessels in the umbilical cord. They carry oxygenated, nutrient-rich blood from the mother to the FETUS via the PLACENTA. In humans, there is normally one umbilical vein.Vitrectomy: Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma.Gene Expression Regulation: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.Mice, Inbred C57BLVitreous Body: The transparent, semigelatinous substance that fills the cavity behind the CRYSTALLINE LENS of the EYE and in front of the RETINA. It is contained in a thin hyaloid membrane and forms about four fifths of the optic globe.Proto-Oncogene Proteins: Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Macular Edema: Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Cell Movement: The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Mice, Transgenic: Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.Fibroblast Growth Factor 2: A single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to FIBROBLAST GROWTH FACTOR 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 1).Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Phosphorylation: The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Mice, Knockout: Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Rats, Sprague-Dawley: A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.Cell Line, Tumor: A cell line derived from cultured tumor cells.Cell Line: Established cell cultures that have the potential to propagate indefinitely.

Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3. (1/589)

Using homology-based PCR, we have isolated cDNA encoding a novel member (491 amino acids) of the angiopoietin (Ang) family from human adult heart cDNA and have designated it angiopoietin-3 (Ang3). The NH2-terminal and COOH-terminal portions of Ang-3 contain the characteristic coiled-coil domain and fibrinogen-like domain that are conserved in other known Angs. Ang3 has a highly hydrophobic region at the N-terminus (approximately 21 amino acids) that is typical of a signal sequence for protein secretion. Ang3 mRNA is most abundant in adrenal gland, placenta, thyroid gland, heart and small intestine in human adult tissues. Additionally, Ang3 is a secretory protein, but is not a mitogen in endothelial cells.  (+info)

Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. (2/589)

The angiopoietins have recently joined the members of the vascular endothelial growth factor family as the only known growth factors largely specific for vascular endothelium. The angiopoietins include a naturally occurring agonist, angiopoietin-1, as well as a naturally occurring antagonist, angiopoietin-2, both of which act by means of the Tie2 receptor. We now report our attempts to use homology-based cloning approaches to identify new members of the angiopoietin family. These efforts have led to the identification of two new angiopoietins, angiopoietin-3 in mouse and angiopoietin-4 in human; we have also identified several more distantly related sequences that do not seem to be true angiopoietins, in that they do not bind to the Tie receptors. Although angiopoietin-3 and angiopoietin-4 are strikingly more structurally diverged from each other than are the mouse and human versions of angiopoietin-1 and angiopoietin-2, they appear to represent the mouse and human counterparts of the same gene locus, as revealed in our chromosomal localization studies of all of the angiopoietins in mouse and human. The structural divergence of angiopoietin-3 and angiopoietin-4 appears to underlie diverging functions of these counterparts. Angiopoietin-3 and angiopoietin-4 have very different distributions in their respective species, and angiopoietin-3 appears to act as an antagonist, whereas angiopoietin-4 appears to function as an agonist.  (+info)

Angiopoietin-1 is an apoptosis survival factor for endothelial cells. (3/589)

We examined the effect of angiopoietin-1 (Ang1) on apoptosis in human umbilical vein endothelial cells (HUVECs). Ang1 (5-1000 ng/ml) dose-dependently inhibited apoptosis under a serum-deprived state. A significant apoptotic inhibition occurred with as low as 50 ng/ml. Two hundred ng/ml of Ang1 inhibited to approximately 50% of the control apoptotic rates for 96 h. Furthermore, an augmented antiapoptotic effect of Ang1 by the addition of 20 ng/ml vascular endothelial growth factor was observed. This Ang1-induced strong antiapoptotic effect in endothelial cells is a novel and intriguing finding and could be an additional description of Ang1-induced direct biological function.  (+info)

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. (4/589)

In contrast with the prevailing view that most tumors and metastases begin as avascular masses, evidence is presented here that a subset of tumors instead initially grows by coopting existing host vessels. This coopted host vasculature does not immediately undergo angiogenesis to support the tumor but instead regresses, leading to a secondarily avascular tumor and massive tumor cell loss. Ultimately, however, the remaining tumor is rescued by robust angiogenesis at the tumor margin. The expression patterns of the angiogenic antagonist angiopoietin-2 and of pro-angiogenic vascular endothelial growth factor (VEGF) suggest that these proteins may be critical regulators of this balance between vascular regression and growth.  (+info)

The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. (5/589)

The MEF2 family of transcription factors has been implicated in transcriptional regulation in a number of different cell types. Targeted deletion of the MEF2C gene, in particular, revealed its importance for early cardiogenesis (Q. Lin et al., 1997, Science 276, 1404-1407). We report here that this deletion also resulted in vascular anomalies characterized by extreme variability in lumen size and defects in remodeling. While primary vascular networks formed in the yolk sac of the mutants, they failed to remodel into more complex vascular structures. Likewise, although the primordia of the dorsal aortae formed normally, anomalies were observed in these vessels later in development. Dorsal and anterior to the heart, the aortae exhibited abnormally small lumens, as did the anterior cardinal veins and intersegmental arteries. In contrast, the dorsal aortae and intersegmental arteries caudal to the heart were grossly enlarged. Cranial vessels were also enlarged and less branched than normal. Endocardiogenesis in the mutant was abnormal with the endothelial cells exhibiting a number of aberrant phenotypes. These endocardial defects were accompanied by a notable reduction in angiopoietin 1 and VEGF mRNA production by the myocardium, indicating that MEF2C is required for myocardial expression of these important endothelial-directed cytokines and thus for correct endocardial morphogenesis.  (+info)

Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. (6/589)

PURPOSE: To elucidate the potential role of angiopoietins and the Tie2 system in choroidal neovascularization. METHODS: Surgically excised choroidal neovascular membranes (CNVMs) were obtained at vitrectomy from five eyes with age-related macular degeneration, three eyes with idiopathic neovascular maculopathy, and two eyes had degenerative myopia and two eyes had angioid streaks. Light microscopic immunohistochemistry was performed to detect cytokines such as vascular endothelial growth factor (VEGF), Ang1, and Ang2 and cellular components such as retinal pigment epithelial (RPE) cells, macrophages, and endothelial cells. Immunofluorescent double staining using confocal microscopy was performed to identify the cell types that secrete specific cytokines. RESULTS: Ang1 and Ang2 were positive in all surgically excised CNVMs, regardless of the primary disease. Double staining revealed that many of the cytokeratin, CD68 and factor VIII positive cells also had Ang1 and Ang2 immunoreactivities. In contrast to Ang1, Ang2 immunoreactivity tends to be higher in the highly vascularized regions of many CNVMs, and the localization was very similar to that of VEGF staining. Almost all vascular structures had prominent immunoreactivity for Tie2, which was confirmed by double staining for Tie2 and factor VIII. Tie2 immunoreactivity was also observed in the RPE monolayer and in pigmented, polygonal, and fibroblast-like cells in the stroma. CONCLUSIONS: Present findings that Ang2 and VEGF are co-upregulated and that Tie2 is expressed in a variety of cell types in CNVMs further support a crucial role of the interaction between VEGF and Ang2 in pathologic angiogenesis of CNVM formation.  (+info)

Expression of angiopoietin-1, angiopoietin-2, and the Tie-2 receptor tyrosine kinase during mouse kidney maturation. (7/589)

The Tie-2 receptor tyrosine kinase transduces embryonic endothelial differentiation, with Angiopoietin-1 (Ang-1) acting as a stimulatory ligand and Ang-2 postulated to be a naturally occurring inhibitor. Expression of these genes was sought during mouse kidney maturation from the onset of glomerulogenesis (embryonic day 14 [E14]) to the end of nephron formation (2 wk postnatal [P2]), and during medullary maturation into adulthood (P8). Using Northern and slot blotting of RNA extracted from whole organs, these three genes were expressed throughout the experimental period with peak levels at P2 to P3. By in situ hybridization analysis at E18, P1, and P3, Ang-1 mRNA was found to localize to condensing renal mesenchymal cells, proximal tubules, and glomeruli in addition to maturing tubules of the outer medulla. In contrast, Ang-2 transcripts were more spatially restricted, being detected only in differentiating outer medullary tubules and the vasa recta bundle area. Using in situ hybridization and immunohistochemistry, Tie-2 was detected in capillaries of the nephrogenic cortex, glomerular tufts, cortical interstitium, and medulla including vessels in the vasa recta. Using Western blotting of protein extracted from whole organs, Tie-2 protein was detected between E14 and P8 with tyrosine phosphorylated Tie-2 evident from E18. These data are consistent with the hypothesis that Tie-2 has roles in maturation of both glomeruli and vasa rectae.  (+info)

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. (8/589)

Our analyses in several different tumor settings challenge the prevailing view that malignancies and metastases generally initiate as avascular masses that only belatedly induce vascular support. Instead, we find that malignant cells rapidly co-opt existing host vessels to form an initially well-vascularized tumor mass. Paradoxically, the co-opted vasculature does not undergo angiogenesis to support the growing tumor, but instead regresses (perhaps as part of a normal host defense mechanism) via a process that involves disruption of endothelial cell/smooth muscle cell interactions and endothelial cell apoptosis. This vessel regression in turn results in necrosis within the central part of the tumor. However, robust angiogenesis is initiated at the tumor margin, rescuing the surviving tumor and supporting further growth. The expression patterns of Angiopoietin-2 (the natural antagonist for the angiogenic Tie2 receptor) and vascular endothelial growth factor (VEGF) strongly implicate these factors in the above processes. Angiopoietin-2 is highly induced in co-opted vessels, prior to VEGF induction in the adjacent tumor cells, providing perhaps the earliest marker of tumor vasculature and apparently marking the co-opted vessels for regression. Subsequently, VEGF upregulation coincident with Angiopoietin-2 expression at the tumor periphery is associated with robust angiogenesis. Thus, in tumors, Angiopoietin-2 and VEGF seem to reprise the roles they play during vascular remodeling in normal tissues, acting to regulate the previously underappreciated balance between vascular regression and growth.  (+info)

To test the hypothesis that the concentration of angiopoietin-2 relative to angiopoietin-1 may be a useful biological marker of mortality in acute lung injury patients. We also tested the association of concentration of angiopoietin-2 relative to ang
TY - JOUR. T1 - Systemic analysis of tyrosine phosphorylated proteins in angiopoietin-1 induced signaling pathway of endothelial cells. AU - Kim, Young-Mee. AU - Seo, Jawon. AU - Yung, Hee Kim. AU - Jeong, Jaeho. AU - Hye, Joon Joo. AU - Lee, Dong Hee. AU - Gou, Young Koh. AU - Lee, Kong Joo. PY - 2007/8/1. Y1 - 2007/8/1. N2 - Angiogenesis is an essential process in physiological and pathological processes and is well-regulated to maintain the cellular homeostasis by balancing the endothelial cells in proliferation and apoptosis. Angiopoietin-1 (Ang1) regulates angiogenesis as a ligand of Tie 2 receptor tyrosine kinase. However, the regulation pathways are not well-understood. To date, only a few of the signaling molecules involved in the Tie 2 receptor tyrosine kinase-mediated angiogenesis have been identified. In this study, we systematically identified tyrosine-phosphorylated proteins in Ang1-induced signaling cascade in human umbilical vein endothelial cells (HUVECs), employing proteomic ...
The angiopoietin/Tie (ANG/Tie) receptor system controls developmental and tumor angiogenesis, inflammatory vascular remodeling, and vessel leakage. ANG1 is a Tie2 agonist that promotes vascular stabilization in inflammation and sepsis, whereas ANG2 is a context-dependent Tie2 agonist or antagonist. A limited understanding of ANG signaling mechanisms and the orphan receptor Tie1 has hindered development of ANG/Tie-targeted therapeutics. Here, we determined that both ANG1 and ANG2 binding to Tie2 increases Tie1-Tie2 interactions in a β1 integrin-dependent manner and that Tie1 regulates ANG-induced Tie2 trafficking in endothelial cells. Endothelial Tie1 was essential for the agonist activity of ANG1 and autocrine ANG2. Deletion of endothelial ...
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases
Effects of Protein and Gene Transfer of the Angiopoietin-1 Fibrinogen-like Receptor-binding Domain on Endothelial and Vessel ...
The results of the present study indicate that TAK1 acts as an AMPKα1 kinase in endothelial cells and positively regulates VEGF-induced, TNF-α-induced, and IL-1β-induced angiogenesis by increasing the expression of the antioxidative mitochondrial enzyme, SOD2. Indeed, superoxide production and the mitochondrial membrane potential were reduced in the absence of TAK1, and the impaired endothelial cell sprouting from aortic rings from TAKΔEC and AMPKα1ΔEC mice was rescued in the presence of PEG-SOD.. The global deletion of TAK1 impairs embryonic development in C. elegans,23 zebrafish, and mice.13 Both the global and endothelial-specific deletions of TAK1 result in vascular malformation, dilated capillaries, and defects in vascular stabilization,14 and correlate well with the phenotype of endothelial cell-specific TGF-β type II receptor conditional mutants.24 In addition to its role in vascular development, TAK1 has also been implicated in the TGF-β-induced regulation of matrix ...
In the circulatory system, while larger features of the vasculature such as arteries and veins appear to be statically positioned for years of use, finer features in the human body and in biology relates to a continuous branching out of a circulatory network that is required for tissue growth. This process is related to biochemical pathways and is vital to be understood so that issues in health and disease can be better addressed. Angiogenesis is the formation of new blood vessels from existing vessels. A functional vascular network is established by balanced angiogenesis processes. While the activation of angiogenesis extends vascular networks crucial for tissue growth, angiogenic vessels should be stabilized to undertake necessary vascular functions. The Notch pathway is fundamental for allowing for vascular stabilization. It acts by preventing excessive angiogenesis. However, how this signaling pathway that is conserved in various biological processes can induce changes that are ...
In this study we found that: (1) LS inhibits tubule formation in HUVECs and HMECs, but not BAECs, however CM from laminar sheared BAECs can inhibit tubule formation of HUVECs, (2) Preconditioning with LS inhibits migration in HUVECs and BAECs, whereas OS does not inhibit migration and this is mediated through secreted protein, (3) Ang2 is downregulated by LS both at the gene and protein level in vitro, (4) Ang2 is downregulated at sites of LS and upregulated at sites of OS in vivo, (5) Knockdown of Ang2 inhibits OS-mediated tubule formation and migration, and (6) Addition of recombinant Ang2 partially rescues LS-inhibited tubule formation. Collectively, these findings suggest that Ang2 secreted by ECs in response to OS, acts as a promigratory and proangiogenic molecule that could play an important role in diseases with altered shear stress.. Fluid shear stress is thought to play a role in angiogenesis and arteriogenesis. In angiogenesis, endothelial proliferation and migration are 2 important ...
The interaction between fluid status and angiopoietin-2 in adverse renal outcomes of chronic kidney disease. Yi-Chun Tsai, Yi-Wen Chiu, Hung-Tien Kuo, Jia-Jung Lee, Su-Chu Lee, Tzu-Hui Chen, Ming-Yen Lin, Shang-Jyh Hwang, Mei-Chuan Kuo, Ya-Ling Hsu, Hung-Chun Chen. Journal article , Research Article , Published 23 Mar 2017 , PLOS ONE ...
Looking for online definition of angiopoietin-2a in the Medical Dictionary? angiopoietin-2a explanation free. What is angiopoietin-2a? Meaning of angiopoietin-2a medical term. What does angiopoietin-2a mean?
TY - JOUR. T1 - Angiopoietin-1 regulates brain endothelial permeability through PTPN-2 mediated tyrosine dephosphorylation of occludin. AU - Siddiqui, M. Rizwan. AU - Mayanil, Chandra S.. AU - Kim, Kwang Sik. AU - Tomita, Tadanori. PY - 2015/6/19. Y1 - 2015/6/19. N2 - Objective Blood brain barrier (BBB) breakdown and increased endothelial permeability is a hallmark of neuro-vascular inflammation. Angiopoietin-1 (Ang-1), a Tie-2 receptor agonist ligand, is known to modulate barrier function of endothelial cells; however the molecular mechanisms related to Ang-1 mediated repair of Tight Junctions (TJs) in brain endothelium still remain elusive. In this study, we investigated a novel role of non-receptor protein tyrosine phosphatase N-2 (PTPN-2) in Ang-1 mediated stabilization of tight junction proteins. Method and Result To study the barrier protective mechanism of Ang-1, we challenged human brain microvascular endothelial cells in-vitro, with a potent inflammatory mediator thrombin. By using ...
Angiopoietins are a family of growth factors that are ligands for the tyrosine kinase receptor, Tie2. Angiopoietin 1 (Ang-1) is agonistic for Tie2, plays a key role in blood vessel maturation and stability and has been shown to possess anti-inflammatory properties. However, Tie2 expression has been demonstrated on human neutrophils and the observation that neutrophils migrate in response to Ang-1 in vitro has confounded research into its exact role in inflammation as well as its potential use as a therapeutic agent. We used a mouse model of peritoneal neutrophilic inflammation to determine if Ang-1 could stimulate neutrophil migration in vivo. Tie2 expression was demonstrated on mouse neutrophils. In addition, recombinant human Ang-1 induced significant chemotaxis of isolated mouse neutrophils in a Tie2- and CD18-dependent manner. Subsequently, co-immunoprecipitation of Ang-1 and CD18 demonstrated their interaction. Intraperitoneal injection of an engineered angiopoietin-1, MAT.Ang-1, induced ...
TY - JOUR. T1 - Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats. AU - Mathews Samuel, Samson. AU - Akita, Yuzo. AU - Paul, Debayon. AU - Thirunavukkarasu, Mahesh. AU - Zhan, Lijun. AU - Sudhakaran, Perumana R.. AU - Li, Chuanfu. AU - Maulik, Nilanjana. PY - 2010/1/1. Y1 - 2010/1/1. N2 - OBJECTIVE - Hyperglycemia impairs angiogenesis in response to ischemia, leading to ventricular remodeling. Although the effects of overexpressing angiogenic growth factors have been studied in inducing angiogenesis, the formation of functional vessels remains a challenge. The present study evaluates the reversal of diabetes-mediated impairment of angiogenesis in the infarcted diabetic rat myocardium by proangiogenic gene therapy. RESEARCH DESIGN AND METHODS - Ad.VEGF and Ad.Ang1 were intramyocardially administered in combination immediately after myocardial ...
Angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) play complementary roles in vascular development during embryogenesis. In the adult, VEGF signaling increases vascular permeability and Ang1 blocks this VEGF-mediated response. Gavard et al. provide evidence that this function of Ang1 is mediated by its actions on the endothelial cells, preventing them from responding to VEGF signaling that triggers disruption of adherens junctions. When injected subcutaneously in mice, Ang1 prevented dermal vascular permeability in response to VEGF injection (acute in vivo vascular permeability model). Experiments with cultured mouse endothelial cells revealed that Ang1 did not prevent VEGF from stimulating downstream effectors involved in proliferation (phosphorylation of Akt, extracellular signal-regulated kinases 1 and 2, and focal adhesion kinase) but did prevent disruption of endothelial barrier function by VEGF. Preexposure of endothelial cell cultures to Ang1 inhibited the ability of ...
TY - JOUR. T1 - Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription. AU - Yao, Dachun. AU - Taguchi, Tetsuya. AU - Matsumura, Takeshi. AU - Pestell, Richard. AU - Edelstein, Diane. AU - Giardino, Ida. AU - Suske, Guntram. AU - Ahmed, Naila. AU - Thornalley, Paul J.. AU - Sarthy, Vijay P.. AU - Hammes, Hans Peter. AU - Brownlee, Michael. PY - 2006/1/27. Y1 - 2006/1/27. N2 - Methylglyoxal is a highly reactive dicarbonyl degradation product formed from triose phosphates during glycolysis. Methylglyoxal forms stable adducts primarily with arginine residues of intracellular proteins. The biologic role of this covalent modification in regulating cell function is not known. Here, we report that in retinal Müller cells, increased glycolytic flux causes increased methylglyoxal modification of the corepressor mSin3A. Methylglyoxal modification of mSin3A results in increased recruitment of O-GlcNAc transferase to an mSin3A-Sp3 complex, with consequent increased ...
Emerging evidence indicates that angiopoietin-2 (Angpt2), a well-recognized vascular destabilizing factor, is a biomarker of poor outcome in ischemic heart disease. However, its precise role in postischemic cardiovascular remodeling is poorly understood. Here, we show that Angpt2 plays multifaceted roles in the exacerbation of cardiac hypoxia and inflammation after myocardial ischemia. Angpt2 was highly expressed in endothelial cells at the infarct border zone after myocardial infarction (MI) or ischemia/reperfusion injury in mice. In the acute phase of MI, endothelial-derived Angpt2 antagonized Angpt1/Tie2 signaling, which was greatly involved in pericyte detachment, vascular leakage, increased adhesion molecular expression, degradation of the glycocalyx and extracellular matrix, and enhanced neutrophil infiltration and hypoxia in the infarct border area. In the chronic remodeling phase after MI, endothelial- and macrophage-derived Angpt2 continuously promoted abnormal vascular remodeling and ...
This study demonstrates the distinct spatiotemporal expression profile of Angpt2 after MI and I/R, which, to date, has been obscure due to a lack of reliable antibodies (54). Using our recently developed anti-Angpt2 antibody (23), which is highly sensitive and specific to Angpt2, we demonstrate distinct expressions of Angpt2 on the ECs and proinflammatory macrophages after ischemia. This prompted us to further investigate the role of Angpt2 in postischemic cardiovascular remodeling. We recently reported that the FOXO1/Angpt2 axis suppresses the endothelial PI3K/Akt-signaling pathway, the main downstream pathway for Tie2 that plays a vital role in maintaining vascular integrity, inducing vascular destabilization in a positive feedback manner (25), and that it is central to the pathogenesis of sepsis (23), diabetic retinopathy (25), and tumor vessel destabilization (38). This study provides additional insights into the serious detrimental effects of the FOXO1/Angpt2 axis in exacerbating cardiac ...
Sphingosine-1-phosphate (S1P) is the endogenous ligand for the sphingosine-1-phophate receptors (S1P1-5) and triggers a number of cellular responses through their stimulation. S1P and its interaction with the S1P receptors play a significant role in a variety of biological processes including vascular stabilization, heart development, lymphocyte homing, and cancer angiogenesis. Agonism of S1P1, especially, has been shown to play an important role in lymphocyte trafficking from the thymus and secondary lymphoid organs, inducing immunosuppression, which has been established as a novel mechanism of treatment for immune diseases and vascular diseases. Sphingosine-1 -phosphate (SlP) has been demonstrated to induce many cellular effects, including those that result in platelet aggregation, cell proliferation, cell morphology, tumor cell invasion, endothelial cell and leukocyte chemotaxis, endothelial cell in vitro angiogenesis, and lymphocyte trafficking. SlP receptors are therefore good targets for a ...
Commander Angiopoietin 2 kit ELISA pour beaucoup de réactivité. Poulet, Boeuf (Vache), Chien et plus. Comparez Angiopoietin 2 kit ELISA et trouvez le bon produit chez anticorps-enligne.fr.
To investigate the theory, Bhandari and colleagues first tested a cohort of lung secretion samples taken from premature infants. After testing the samples, the researchers found that miR-34a was significantly increased only in the samples taken from babies who went on to develop BPD. The researchers also tested lung tissue collected postmortem from babies who had died at different ages from lung disease. Again, they found that this particular microRNA was expressed in the samples and also its downstream targets (the production of proteins) were suppressed in the ones with BPD. Next, the researchers found that levels of miR-34a levels were increased in the lungs of neonatal mice exposed to high levels of oxygen. Bhandari and his team then blocked the microRNA by repressing gene expression, as well as pharmacologically, by injecting the mouse models with the downstream target of the miR-34a, angiopoietin-1. Blocking miR-34a or injecting angiopoietin-1 in the mouse models improved their lung ...
Gentaur molecular products has all kinds of products like :search , Reliatech \ Human Angiopoietin_1 _ Ang_1 Source HeLa cells \ 300-047 for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , Reliatech \ Anti_Mouse, mab Angiopoietin_like protein 3 Source Rat \ 103-M307 for more molecular products just contact us
Polyclonal antibody for Angiopoietin 2/ANGPT2 detection. Host: Rabbit.Size: 100μg/vial. Tested applications: IHC-P. Reactive species: Human. Angiopoietin 2/ANGPT2 information: Molecular Weight: 56919 MW; Subcellular Localization: Secreted.
Yn aml mae gan enynnau lawer o gyfystyron. Mae hyn oherwydd eu bod yn aml yn cael eu darganfod gan nifer o bobl mewn cyd-destunau gwahanol heb wybod mair un genynnau oeddyn nhw. Hefyd mae gan wahanol gymunedau gwyddonol safonau gwahanol ar gyfer enwi genynnau. Dyma restr o gyfystyron ar gyfer y genyn ANGPT2. ...
Affiliation:名古屋市立大学,大学院医学研究科,講師, Research Field:Ophthalmology, Keywords:脈絡膜新生血管,炎症,加齢黄斑変性,ペリサイト,細胞生物学,リポフスチン,Angiopoietin-2,マウス,発現抑制,脂質, # of Research Projects:5, # of Research Products:33, Ongoing Project:加齢黄斑変性の病態におけるブルッフ膜への加齢性沈着脂質の役割の解明
Angiopoietin 2 antibody (angiopoietin 2) for ELISA, IHC-P, WB. Anti-Angiopoietin 2 pAb (GTX10601) is tested in Human samples. 100% Ab-Assurance.
Angiopoietin 1兔多克隆抗体(ab94684)可与小鼠, 人样本反应并经WB, IHC实验严格验证并得到1个独立的用户反馈。所有产品均提供质保服务,中国75%以上现货。
Published data on the role of the Ang/tie-2 system in cardiovascular diseases are limited. Most of our knowledge regarding the angiopoietins has come from oncology studies where angiogenesis is a prerequisite for tumor growth and metastasis. Indeed, Ang-2 has been shown to be a marker of a poor prognosis in breast cancer and non-small cell lung cancer (4,21). In the present paper, we describe a new assay for Ang-1 and, in addition, have demonstrated (for the first time in the literature) very abnormal levels of Ang-2 and tie-2, but normal Ang-1, in CHF. Vascular endothelial growth factor was marginally raised in the patients, suggesting that Ang-2 may be more relevant to the pathophysiology of this disease. In addition, there was a significant correlation between Ang-2 and tie-2.. That Ang-1 is not raised in CHF is consistent with currently held views that its secretion is not stimulated by hypoxia, as demonstrated in animal studies (13,14,22). Angiopoietin-1 has been shown to have antiapoptotic ...
Background: Microcirculatory dysfunction is associated with multiple organ failure and unfavorable patient outcome. We investigated whether therapeutically targeting the endothelial angiopoietin/Tie2 system preserves microvascular integrity during hemorrhagic shock. Methods: Rats were treated with the angiopoietin-1 mimetic vasculotide and subjected to hemorrhagic shock and fluid resuscitation. Microcirculatory perfusion and leakage were assessed with intravital microscopy (n = 7 per group) and Evans blue dye extravasation (n = 8 per group), respectively. The angiopoietin/Tie2 system was studied at protein and RNA level in plasma, kidneys, and lungs. Results: Hemorrhagic shock significantly reduced continuously perfused capillaries (7 ± 2 vs. 11 ± 2) and increased nonperfused vessels (9 ± 3 vs. 5 ± 2) during hemorrhagic shock, which could not be restored by fluid resuscitation. Hemorrhagic shock increased circulating angiopoietin-2 and soluble Tie2 significantly, which associated with ...
Angiopoietin-related protein 2 also known as angiopoietin-like protein 2 is a protein that in humans is encoded by the ANGPTL2 gene. Angiopoietin-like protein 2 maintains tissue homeostasis by promoting adaptive inflammation and subsequent tissue reconstruction, whereas an excess of ANGPTL2 activation induced by prolonged stress promotes the breakdown of tissue homeostasis due to chronic inflammation, promoting the development of metabolic diseases. ANGPTL2 has a role also in angiogenesis, in tissue repair, in obesity, in atherosclerotic diseases and finally in cancerogenesis. Angiopoietins are members of the vascular endothelial growth factor family and the only known growth factors largely specific for vascular endothelium. Angiopoietin-1, angiopoietin-2, and angiopoietin-4 participate in the formation of blood vessels. ANGPTL2 protein is a secreted glycoprotein with homology to the angiopoietins and may exert a function on endothelial cells through autocrine or paracrine action. GRCh38: ...
Background. In sepsis and various other inflammatory conditions, elevated circulating levels of angiopoietin-2 (Ang2) are detected, but the precise functional role of Ang2 in these conditions is not well understood. Here, we investigated the contribution of Ang2 to the inflammatory response and renal function impairment in a mouse model of endotoxaemia.. Methods. Ang2-deficient mice and wild-type littermates were challenged with lipopolysaccharide [LPS; 1500 EU/g, intraperitoneal (i.p.)]. In additional experiments, wild-type C57Bl/6 mice were depleted of circulating neutrophils by antibody treatment (NIMPR14) prior to LPS challenge to study the role of neutrophils in regulating LPS-induced cytokine release. After 8 or 24 h of LPS challenge, the mice were sacrificed and organs were harvested. Quantitative reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay were performed for endothelial adhesion molecules (P-selectin, E-selectin, VCAM-1 and ICAM-1) and plasma ...
Hyperoxia-induced acute lung injury (HALI) is a key contributor to the pathogenesis of bronchopulmonary dysplasia (BPD) in neonates, for which no specific preventive or therapeutic agent is available. Here we show that lung micro-RNA (miR)-34a levels are significantly increased in lungs of neonatal mice exposed to hyperoxia. Deletion or inhibition of miR-34a improves the pulmonary phenotype and BPD-associated pulmonary arterial hypertension (PAH) in BPD mouse models, which, conversely, is worsened by miR-34a overexpression. Administration of angiopoietin-1, which is one of the downstream targets of miR34a, is able to ameliorate the BPD pulmonary and PAH phenotypes. Using three independent cohorts of human samples, we show that miR-34a expression is increased in type 2 alveolar epithelial cells in neonates with respiratory distress syndrome and BPD. Our data suggest that pharmacologic miR-34a inhibition may be a therapeutic option to prevent or ameliorate HALI/BPD in neonates.
Mice. Specific pathogen-free (SPF) C57BL/6J mice (catalog 000664), Tie2-GFP mice (catalog 003658), and UBC-Cre-ERT2 mice (catalog 007001) were purchased from the Jackson Laboratory. Angpt1fl/fl mice were a gift from Yoshikazu Nakaoka (Osaka University, Osaka, Japan), Angpt1-GFP mice were a gift from Sean J. Morrison (University of Texas Southwestern, Dallas, Texas, USA), Angpt2-lacZ mice were a gift from Nicholas Gale (Regeneron Pharmaceuticals), and Vegfr2fl/fl mice were a gift from Masanori Hirashima (Kobe University, Kobe, Japan). Prox1-GFP (30), Angpt1-GFP (33), Prox1fl/fl (39), Tie2fl/fl (35), Angpt1fl/fl (36, 37), Angpt2fl/fl (38), Vegfr2fl/fl (55), and Angpt2-lacZ (22) mice were transferred and bred in our SPF animal facility at KAIST. To deplete Prox1, Tie2, or Vegfr2 genes specifically in ECs, VE-cadherin-Cre-ERT2 mice (34) were mated with either Prox1fl/fl, Tie2fl/fl, or Vegfr2fl/fl mice to obtain EC-specific Prox1-, Tie2-, or Vegfr2-deleted mice, respectively, in a tamoxifen-dependent ...
Human platelet lysate (PL) is a cost-effective and human source of autologous multiple and potent pro-angiogenic factors, such as vascular endothelial growth factor A (VEGF A), fibroblast growth factor b (FGF b) and angiopoietin-1. Nanocoatings previously characterized were prepared by layer-by-layer assembling incorporating PL with marine-origin polysaccharides and were shown to activate human umbilical vein endothelial cells (HUVECs). Within 20 h of incubation, the more sulfated coatings induced the HUVECS to the form tube-like structures accompanied by an increased expression of angiogenic-associated genes, such as angiopoietin-1 and VEGF A. This may be a cost-effective approach to modify 2D/3D constructs to instruct angiogenic cells towards the formation of neo-vascularization, driven by multiple and synergistic stimulations from the PL combined with sulfated polysaccharides.. ...
ENCODES a protein that exhibits identical protein binding (ortholog); INVOLVED IN animal organ regeneration (ortholog); liver regeneration (ortholog); negative regulation of apoptotic process (ortholog); PARTICIPATES IN angiopoietin signaling pathway; ASSOCIATED WITH brain ischemia (ortholog); Diabetes Mellitus, Experimental (ortholog); diabetic retinopathy (ortholog); FOUND IN extracellular space (inferred); integral component of membrane (inferred); membrane raft (inferred)
Purified Recombinant Human ANGPT1/COMP protein, FLAG-tagged from Creative Biomart. Recombinant Human ANGPT1/COMP protein, FLAG-tagged can be used for research.
401366DNAHomo sapiens 1gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60tcctgtgcag tctctggatt cacctttagt agctattgga tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg ggtggccaac ataaagcaag atggaagtga gaaatactat 180gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatcaa 300ggtatagcag tggctgggcc ctttgactac tggggccagg gaaccctggt caccgtctcc 360tcagcc 3662122PRTHomo Sapiens 2Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp Gln Gly Ile Ala Val Ala Gly Pro Phe Asp Tyr Trp Gly 100 105 110Gln Gly Thr Leu Val Thr Val Ser ...
Thank you for your interest in spreading the word about Science.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
ANGPT2 (Human) ELISA Kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human ANGPT2. (KA1867) - Products - Abnova
Detect and quantitate human angiopoietin 1 (ANGPT1) in buffered solution and cell culture supernatants using a homogeneous LANCE Ultra TR-FRET assay.
Camenisch G et al. (2002) ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo.. [^] ...
Special note about Community Feature Content. Any content and/or opinions uploaded, expressed or submitted through any Community Feature or any other publicly available section of the Web Site (including password-protected areas), and all articles and responses to questions, other than the content explicitly authorized by the Company, are solely the opinions and responsibility of the person or entity submitting them and do not necessarily reflect the opinions of the Company. By way of example, any recommended or suggested use of products or services available from the Company that is posted through a Community Feature is not a sign of approval or recommendation by the Company. If you choose to follow any such recommendation you do so at your own risk.. Links to Third Party Sites. The Web Site may contain links to other websites on the internet. The Company is not responsible for the content, products, services or practices of any third party websites, including without limitation sites linked to ...
Utilization of cylindrical roller linear guide that up-level the parallelism between molds, and improve the cleanless circumstance around mold by lubrication-free on tie bar for its guider function has been replaced. ...
AGPT2 - Angpt2 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector shRNA available for purchase from OriGene - Your Gene Company.
Primary congenital glaucoma (PCG) is a leading cause of blindness in children worldwide and is caused by developmental defects in 2 aqueous humor outflow structures, Schlemms canal (SC) and the trabecular meshwork. We previously identified loss-of-function mutations in the angiopoietin (ANGPT) receptor TEK in families with PCG and showed that ANGPT/TEK signaling is essential for SC development. Here, we describe roles for the major ANGPT ligands in the development of the aqueous outflow pathway. We determined that ANGPT1 is essential for SC development, and that Angpt1-knockout mice form a severely hypomorphic canal with elevated intraocular pressure. By contrast, ANGPT2 was dispensable, although mice deficient in both Angpt1 and Angpt2 completely lacked SC, indicating that ANGPT2 compensates for the loss of ANGPT1. In addition, we identified 3 human subjects with rare ANGPT1 variants within an international cohort of 284 PCG patients. Loss of function in 2 of the 3 patient alleles was observed ...
Primary congenital glaucoma (PCG) is a leading cause of blindness in children worldwide and is caused by developmental defects in 2 aqueous humor outflow structures, Schlemms canal (SC) and the trabecular meshwork. We previously identified loss-of-function mutations in the angiopoietin (ANGPT) receptor TEK in families with PCG and showed that ANGPT/TEK signaling is essential for SC development. Here, we describe roles for the major ANGPT ligands in the development of the aqueous outflow pathway. We determined that ANGPT1 is essential for SC development, and that Angpt1-knockout mice form a severely hypomorphic canal with elevated intraocular pressure. By contrast, ANGPT2 was dispensable, although mice deficient in both Angpt1 and Angpt2 completely lacked SC, indicating that ANGPT2 compensates for the loss of ANGPT1. In addition, we identified 3 human subjects with rare ANGPT1 variants within an international cohort of 284 PCG patients. Loss of function in 2 of the 3 patient alleles was observed ...
Liver regeneration requires spatially and temporally precisely coordinated proliferation of the two major hepatic cell populations, hepatocytes and liver sinusoidal endothelial cells (LSECs), to reconstitute liver structure and function. The underlying mechanisms of this complex molecular cross-talk remain elusive. Here, we show that the expression of Angiopoietin-2 (Ang2) in LSECs is dynamically regulated after partial hepatectomy. During the early inductive phase of liver regeneration, Ang2 down-regulation leads to reduced LSEC transforming growth factor-β1 production, enabling hepatocyte proliferation by releasing an angiocrine proliferative brake. During the later angiogenic phase of liver regeneration, recovery of endothelial Ang2 expression enables regenerative angiogenesis by controlling LSEC vascular endothelial growth factor receptor 2 expression. The data establish LSECs as a dynamic rheostat of liver regeneration, spatiotemporally orchestrating hepatocyte and LSEC proliferation ...
The functional consequences of angiopoietin/Tie-2 signaling have been well established through genetic loss-of-function and gain-of-function experiments (Carmeliet, 2003; Maisonpierre et al., 1997; Suri et al., 1996; Yancopoulos et al., 2000). The phenotypes of Ang-1- and Ang-2-deficient and -overexpressing mice have led to an agonistic Ang-1/Tie-2 model and an antagonistic Ang-2/Tie-2 model (Hanahan, 1997). According to these, Ang-1 activates Tie-2 and induces subsequent signal transduction promoting endothelial-cell survival, endothelial quiescence and vessel assembly. Conversely, Ang-2 is believed to act as a non-signal-transducing Tie-2 ligand that binds to endothelial Tie-2 and thereby negatively interferes with agonistic Ang-1/Tie-2 functions. As such, it does not exert functions of its own but rather acts as a facilitator of other vascular cytokines. The net outcome of Ang-2 functions is therefore considered to be contextually determined by the presence of other cytokines. For example, ...
Plasmodium knowlesi parasitemia correlated with age (Spearmans correlation coefficient [rs] = 0.36; P < .0001). In knowlesi malaria, IL-6, angiopoietin-2, and microvascular dysfunction were increased in severe compared to nonsevere disease, and all correlated with age, independent of parasitemia. In falciparum malaria, angiopoietin-2 increased with age, independent of parasite biomass (histidine-rich protein 2 [HRP2]). Independent risk factors for severe malaria included parasitemia and angiopoietin-2 in knowlesi malaria, and HRP2, angiopoietin-2, and microvascular dysfunction in falciparum malaria ...
Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE-1) is a tyrosine kinase cell-surface receptor that is expressed primarily in endothelial cells. It exhibits high homology to TEK/TIE-2 and inhibits the binding of TEK/TIE-2 to the growth factor angiopoietin-1. The extracellular domain of TIE-1 can be cleaved by multiple factors, including vascular endothelial growth factor (VEGF); this results in loss of its ability to inhibit TEK/TIE-2. In addition to its role in angiogenesis, TIE-1 is reported to have proinflammatory effects in endothelial cells. TIE-1 is also known as tyrosine-protein kinase receptor Tie-1, TIE, and JTK14.. ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 1][2][3] It belongs to the tyrosine kinase inhibitor family of medications.[4] It is taken by mouth.[4] ... LUX-Lung 1): a phase 2b/3 randomised trial". The Lancet. Oncology. 13 (5): 528-38. doi:10.1016/S1470-2045(12)70087-6. PMID ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... 6 (1): 79-85. doi:10.3758/CABN.6.1.79. PMID 16869232.. *^ a b c d e Baj G, Carlino D, Gardossi L, Tongiorgi E (October 2013). " ... doi:10.1016/S0896-6273(00)80540-1. PMID 9728912. S2CID 13983709.. *^ a b c d e Bartkowska K, Paquin A, Gauthier AS, Kaplan DR, ... 1 (3): 191-98. doi:10.1038/35044558. PMID 11257907. S2CID 9750498.. *^ a b Zhong L, Yan CH, Lu CQ, Xu J, Huang H, Shen XM ( ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... 1 (3): 263-268.. *^ a b "Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment of Neovascular (Wet) Age-Related ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 1 mg, or 3 mg of pegaptanib administered intravitreal injections every 6 weeks. Of the 1200 patients enrolled in the study ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... PDGF[1][2] is a potent mitogen for cells of mesenchymal origin, including fibroblasts, smooth muscle cells and glial cells. In ... 978-1-4160-3121-5. .. *^ Fredriksson, Linda; Li, Hong; Eriksson, Ulf (August 2004). "The PDGF family: four gene products form ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... 6 (1): 79-85. doi:10.3758/CABN.6.1.79. PMID 16869232.. *^ a b c d e Baj G, Carlino D, Gardossi L, Tongiorgi E (October 2013). " ... doi:10.1016/S0896-6273(00)80540-1. PMID 9728912.. *^ a b c d e Bartkowska K, Paquin A, Gauthier AS, Kaplan DR, Miller FD ( ... 41 (1): 22-28. doi:10.1002/eat.20474. PMID 17922530.. *^ a b Vargas-Perez H, Ting-A Kee R, Walton CH, Hansen DM, Razavi R, ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... 1 February 2008. Retrieved 14 November 2019.. *^ a b c d e f g h "Nilotinib Monograph for Professionals". Drugs.com. Retrieved ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 55 (10): 1-6. doi:10.3109/10428194.2014.887714. PMID 24467220.. *^ "FDA Approves Tasigna for Treatment of Philadelphia ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... This article on a gene on human chromosome 1 is a stub. You can help Wikipedia by expanding it.. *v ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 95 (1): 221-30. PMID 10607706.. *. Munthe E, Aasheim HC (2002). "Characterization of the human ephrin-A4 promoter". Biochem. J ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... 15 (1): 11-5. doi:10.1590/s1555-79602013000100004. PMID 23396236.. *^ Yang S, Geng Z, Ma K, Sun X, Fu X (June 2016). "Efficacy ... 6 (1): e1231276. doi:10.1080/21592535.2016.1231276. PMC 5098722. PMID 27740881.. *^ Tenchurin, T.H.; Lyundup, A.V.; Demchenko, ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 156 (1): 16-23. doi:10.1210/en.2014-1596. PMID 25330101.. *^ Gravanis A, Calogeropoulou T, Panoutsakopoulou V, Thermos K, ... 3 (1): 19-24. doi:10.2174/156720506775697061. PMID 16472198.. *^ Reichardt LF (September 2006). "Neurotrophin-regulated ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 1 Reverse signaling in growth cone survival *1.1 Formation of the retinotopic map ... 1995). "Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor involved in axon bundle formation". Neuron. 14 (5 ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 2009 October 1; 119(10). Tang, Dual MET EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung ... Blum G, Gazit A, Levitzki A (2000). "Substrate competitive inhibitors of IGF-1 receptor kinase". Biochemistry. 39 (51): 15705- ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 38 (1): 11-9. doi:10.1080/07853890500442758. PMID 16448984.. *. Ciampi R, Nikiforov YE (2007). "RET/PTC rearrangements and BRAF ... doi:10.1385/EP:13:1:03. PMID 12114746.. *. Santoro M, Melillo RM, Carlomagno F, et al. (2004). "Minireview: RET: normal and ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... Fibroblast growth factor 20 is a protein which in humans is encoded by the FGF20 gene.[1] ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 108 (1): 1-10. PMID 8061955.. *. Gratacòs M, EscaramÃs G, Bustamante M, et al. (2010). "Role of the neurotrophin network in ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ...
Angiopoietin (Ang). *Autocrine motility factor. *Bone morphogenetic proteins (BMPs). *Ciliary neurotrophic factor family * ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... A growth factor is a naturally occurring substance capable of stimulating cellular growth,[1] proliferation, healing, and ... The alpha granules in blood platelets contain growth factors PDGF, IGF-1, EGF, and TGF-β which begin healing of wounds by ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... KGF is a small signaling molecule that binds to fibroblast growth factor receptor 2b (FGFR2b).[1] For signalling to occur, a ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 156 (1): 16-23. doi:10.1210/en.2014-1596. PMID 25330101.. *^ Gravanis A, Calogeropoulou T, Panoutsakopoulou V, Thermos K, ... doi:10.1007/s00018-006-6010-1. PMID 16699811.. *^ Harrington AW, Ginty DD (March 2013). "Long-distance retrograde neurotrophic ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... 9 (1): 83-90. doi:10.3892/mmr.2013.1781. PMID 24213221.. *^ Gauthier A (Feb 2013). "Role of sorafenib in the treatment of ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... 1 (1): 1-3. doi:10.4021/jmc112e. Retrieved 11 February 2014.. *^ FDA Approval letter for use of sorafenib in advanced renal ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... 22 (1): 175-84. doi:10.1200/JCO.2004.05.114. PMID 14701780.. *^ a b Rao, S; Starling, N; Cunningham, D; Benson, M; Wotherspoon ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... It binds to the epidermal growth factor receptor (EGFR) with high affinity.[1] The mouse monoclonal antibody (mAb425) from ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... "Flk-1 as a target for tumor growth inhibition". Cancer Res. 56 (15): 3540-5. PMID 8758924.. ... 1] which was the first description of compounds inhibiting the catalytic activity of the epidermal growth factor receptor (EGFR ...
Angiopoietin-1 receptor also known as CD202B (cluster of differentiation 202B) is a protein that in humans is encoded by the ... Master Z, Jones N, Tran J, Jones J, Kerbel RS, Dumont DJ (Nov 2001). "Dok-R plays a pivotal role in angiopoietin-1-dependent ... Also known as TIE2, it is an angiopoietin receptor. The TEK receptor tyrosine kinase is expressed almost exclusively in ... The ligand for the receptor is angiopoietin-1. Defects in TEK are associated with inherited venous malformations; the TEK ...
Angiopoietin 2. antagonist of angiopoietin 1. TSP-1 and TSP-2. inhibit cell migration, cell proliferation, cell adhesion and ... Meth-1 and Meth-2. IFN-α, -β and -γ, CXCL10, IL-4, -12 and -18. inhibit cell migration of endothelial cells, downregulate bFGF ... 25 (1): 1-10. doi:10.1002/ptr.3224. PMID 20564543.. *^ Izuta, Hiroshi; Chikaraishi, Yuichi; Shimazawa, Masamitsu; Mishima, ... doi:10.1016/s1357-2725(01)00023-1. PMID 11312106.. *^ Rini, BI. (Feb 2007). "Vascular endothelial growth factor-targeted ...
Angiopoietin. *Agonists: Angiopoietin 1. *Angiopoietin 4. *Antagonists: Angiopoietin 2. *Angiopoietin 3. *Kinase inhibitors: ... Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7). *Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) ... Vandetanib is used to treat medullary thyroid cancer in adults who are ineligible for surgery.[1][5][6] ... Common (present in between 1% and 10% of people) adverse effects include pneumonia, sepsis, influenza, cystitis, sinusitis, ...
Li, J. J.; Huang, Y. Q.; Basch, R.; Karpatkin, S. (February 2001). "Thrombin induces the release of angiopoietin-1 from ... Angiopoietin-1) and cytokines including the EMT inducer TGF-β. The release of TGF-β by platelets in blood vessels near primary ... 109 (4 Pt 1): 1495-509. doi:10.1083/jcb.109.4.1495. PMC 2115780 . PMID 2677020. Herfs M, Hubert P, Suarez-Carmona M, Reschner A ... 114 (1): 100-109. doi:10.1016/j.jconrel.2006.04.014. ISSN 0168-3659. PMID 16831482. Gershengorn MC, Hardikar AA, Wei C, et al ...
In the combined absence of angiopoietin 1 and angiopoietin 2, Schlemm's canal and episcleral lymphatic vasculature completely ... 1][2][3][4] It is named after Friedrich Schlemm (1795-1858), a German anatomist. ...
Browse our Angiopoietin-like Protein 1/ANGPTL1 Protein catalog backed by our Guarantee+. ... Angiopoietin-like Protein 1/ANGPTL1 Proteins available through Novus Biologicals. ... angiopoietin Y1 protein, angiopoietin-3 protein, angiopoietin-like 1 protein, Angiopoietin-like protein 1 protein, angiopoietin ... Our Angiopoietin-like Protein 1/ANGPTL1 Peptides and Angiopoietin-like Protein 1/ANGPTL1 Proteins can be used in a variety of ...
1. Dongjun Luo, Zhongxia Wang, Junyi Wu, Chunping Jiang, Junhua Wu, The Role of Hypoxia Inducible Factor-1 in Hepatocellular ... Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell ... Corrections: Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via ... adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma Volume 54, Issue 3, 910-919, Article first ...
Angiopoietin-like protein 4, Lipoprotein lipase, Macrophages, GW501516 National Category Biochemistry and Molecular Biology ... Angiopoietin-like protein (ANGPTL) 4 inactivates LPL and ANGPTL4 expression is controlled by peroxisome proliferator-activated ... We conclude that inactivation of LPL in THP-1 macrophages primarily occurs on the cell surface where oligomers of ANGPTL4 are ... Inactivation of lipoprotein lipase occurs on the surface of THP-1 macrophages where oligomers of angiopoietin-like protein 4 ...
In this study, we hoped to investigate the changes of Angiopoietin-like protein 3(ANGPTL3) levels in hyperlipidemia patients ... Angiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria. ... Angiopoietin-like protein 3(ANGPTL3) is well acknowledged as a key regulator of lipid metabolism. Now, there have not been ... 1. Serum ANGPTL3 in patients with hyperlipidemia related proteinuria was higher than that in the control group, and the ...
... increased angiopoietin-2, and an elevated ratio of angiopoietin-2/angiopoietin-1 in the placenta. This suggests that ... Angiopoietins are proteins with important roles in vascular development and angiogenesis. All angiopoietins bind with similar ... may be associated with a dysregulation in angiopoietins. Increased levels of angiopoietin-1 appear to be associated with a ... Angiopoietin 1 has been shown to interact with TEK tyrosine kinase. Recently, studies in malaria-endemic areas suggest that ...
2005). "Biological characterization of angiopoietin-3 and angiopoietin-4". FASEB J. 18 (11): 1200-8. doi:10.1096/fj.03-1466com ... 1999). "Molecular cloning, expression, and characterization of angiopoietin-related protein. angiopoietin-related protein ... angiopoietin-2, and angiopoietin-4 participate in the formation of blood vessels. The protein encoded by this gene is another ... "Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3". FEBS Lett. 443 (3): 353-6. doi: ...
Buy our Recombinant human Angiopoietin 1 protein. Ab69492 is an active full length protein produced in HeLa cells and has been ... Recombinant human Angiopoietin 1 protein. See all Angiopoietin 1 proteins and peptides. ...
Angiopoietin-1 for Myocardial Angiogenesis , IntechOpen, Published on: 2011-10-21. Authors: Vien Khach Lai, Muhammad Zeeshan ... Angiopoietin-1 for Myocardial Angiogenesis. By Vien Khach Lai, Muhammad Zeeshan Afzal, Muhammad Ashraf and Khawaja Husnain ...
Angiopoietin-1 Uncouples the VEGF Receptor from Src Message Subject. (Your Name) has forwarded a page to you from Science ... J. S. Gutkind, Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev. Cell 14, 25 ... Angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) play complementary roles in vascular development during ... extracellular signal-regulated kinases 1 and 2, and focal adhesion kinase) but did prevent disruption of endothelial barrier ...
We previously identified loss-of-function mutations in the angiopoietin (ANGPT) receptor TEK in families with PCG and showed ... Angiopoietin-1 is required for Schlemms canal development in mice and humans. ... Angiopoietin-1 is required for Schlemms canal development in mice and humans. ... Published December 1, 2017; First published November 6, 2017 Citation Information: J Clin Invest. 2017;127(12):4421-4436. https ...
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.. Davis S1, Aldrich TH, Jones ... The structure of Angiopoietin-1 differs from that of known angiogenic factors or other ligands for receptor tyrosine kinases. ... Although Angiopoietin-1 binds and induces the tyrosine phosphorylation of TIE2, it does not directly promote the growth of ... We report the identification of a secreted ligand for TIE2, termed Angiopoietin-1, using a novel expression cloning technique ...
... angiopoietin 3 , angiopoietin Y1 , angiopoietin-3 , dJ595C2.2 (angiopoietin Y1) , angiopoietin-like protein ... angiopoietin-2, and angiopoietin-4 participate in the formation of blood vessels. The protein encoded by this gene is another ... Angiopoietin-Like 1 (ANGPTL1) Antigen-Profil Beschreibung des Gens Angiopoietins are members of the vascular endothelial growth ... Top Angiopoietin-Like 1 ELISA Kits auf antikoerper-online.de. Showing 10 out of 38 products:. Katalog Nr.. Reaktivität. ...
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.. Suri C1, Jones PF, Patan S, ... Angiopoietin-1 seems to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix ... We have recently cloned a ligand for TIE2, termed Angiopoietin-1. Here we show that mice engineered to lack Angiopoietin-1 ... demonstrating that Angiopoietin-1 is a primary physiologic ligand for TIE2 and that it has critical in vivo angiogenic actions ...
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-1169pmid: ... Angiopoietin-1 promotes neurite outgrowth from dorsal root ganglion cells positive for Tie-2 receptor. Cell Tissue Res 2005;320 ... Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a ... Effect of intracavernous administration of angiopoietin-4 on erectile function in the streptozotocin-induced diabetic mouse. J ...
Holopainen T, Huang H, Chen C, Kim KE, Zhang L, Zhou F, Han W, Li C, Yu J, Wu J, Koh GY, Alitalo K, He Y. Angiopoietin-1 ... Correction: Article on Role of Angiopoietin-1 in Tumor Metastasis Message Subject (Your Name) has forwarded a page to you from ... In the article on the role of angiopoietin-1 in tumor metastasis in the June 1, 2009 issue of Cancer Research ( 1), the authors ... Tanja Holopainen,2 Huilian Huang,1 Caiping Chen,1 Kyung Eun Kim,3 Luqing Zhang,1 Fei Zhou,1 Wencan Han,1 Chaojun Li,1 Jun Yu,4 ...
p,The LEGENDplex™ Human Angiogenesis Panel 1 Mix and Match Capture Beads offer flexible customization within the panel (12-plex ... 740701 LEGENDplex™ Human Angiopoietin-1 Capture Bead A5, 13X. 740702 LEGENDplex™ Human Angiopoietin-2 Capture Bead A6, 13X. ... Human Angiopoietin-1 Capture Bead A5, 13X (Cat. # 740701). • Human Angiogenesis Panel 1 Detection Antibodies (Cat. # 740700). ... Human Angiopoietin-1 Capture Bead A5, 13X (Cat. # 740701). • Human Angiogenesis Panel 1 Detection Antibodies (Cat. # 740700). ...
Angiopoietin-2 dose-dependently blocks directed migration toward Angiopoietin-1. Carlson et al (2001) have shown that Ang-1 ... Angiopoietins can potentiate the effects of other angiogenic cytokines. An investigation of the impact of angiopoietins on ... Angiopoietin 1, KIAA0003, ANG-1, AGP1, AGPT.. Introduction. ANGPT1 is an angiogenic factor which intervenes in blood vessel ... Angiopoietin-1 is a ligand for the receptor-like tyrosine kinase designated TIE-2 (Davis et al, 1996). Binding of Angiopoietin- ...
Kwak HJ, So JN, Lee SJ, Kim I, Koh GY: Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett448 :249 ... Daly C, Wong V, Burova E, Wei Y, Zabski S, Griffiths J, Lai KM, Lin HC, Ioffe E, Yancopoulos GD, Rudge JS: Angiopoietin-1 ... Cho CH, Sung HK, Kim KT, Cheon HG, Oh GT, Hong HJ, Yoo OJ, Koh GY: COMP-angiopoietin-1 promotes wound healing through enhanced ... Brindle NP, Saharinen P, Alitalo K: Signaling and functions of angiopoietin-1 in vascular protection. Circ Res98 :1014 -1023, ...
OMIM: ANGIOPOIETIN-LIKE 1; ANGPTL1*Gene Ontology: Angptl1 *Mouse Phenome DB: Angptl1 *UCSC: Chr.1:156,839,023-156,861,078(+)* ... angiopoietin-like 1. Synonyms: 2810039D03Rik, ANG-3, ANG3, ANGPT3, ANGY, ARP1. Gene nomenclature, locus information, and GO, ... Question? Comments? For Mice, Cells, and germplasm please contact us at [email protected], US 1-888-KOMP-MICE or International ... Vega: OTTMUSG22614 (Angptl1, angiopoietin-like 1)*CCDS: 15397, 15397.1* ...
We also tested the association of concentration of angiopoietin-2 relative to ang ... To test the hypothesis that the concentration of angiopoietin-2 relative to angiopoietin-1 may be a useful biological marker of ... Baseline concentration of angiopoietin-2 relative to angiopoietin-1 was significantly higher in patients who died (median, 58 [ ... OBJECTIVE: To test the hypothesis that the concentration of angiopoietin-2 relative to angiopoietin-1 may be a useful ...
Angiopoietin-1 Promotes Skeletal and Cardiac Myocyte Survival Through Integrins. Susan M. Dallabrida, Nesreen Ismail, Julianne ... Angiopoietin-1 Promotes Skeletal and Cardiac Myocyte Survival Through Integrins. Susan M. Dallabrida, Nesreen Ismail, Julianne ... Angiopoietin-1 Promotes Skeletal and Cardiac Myocyte Survival Through Integrins. Susan M. Dallabrida, Nesreen Ismail, Julianne ...
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade ... Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade ... Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade ... Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade ...
The Effects of Angiopoietin-1 and -2 on Tumor Growth and Angiogenesis in Human Colon Cancer. Syed A. Ahmad, Wenbiao Liu, Young ... In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis.. Exp. ... Kwak H. J., So J. N., Lee S. J., Kim I., Koh G. Y. Angiopoietin-1 is an apoptosis survival factor for endothelial cells.. FEBS ... Angiopoietin (Ang) 1 and Ang-2 are important regulators of endothelial cell survival. Current models suggest that an increase ...
Angiopoietin 1 antibody for Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)). ... Recommended Angiopoietin 1 Antibody (supplied by: Log in to see ) Antigen Angiopoietin 1 (ANGPT1) Antibodies show synonyms for ... This Angiopoietin 1 antibody is un-conjugated Alternatives Biotin. (19), FITC. (16), HRP. (8), APC. (4), PE. (4), Alkaline ... Target Details Angiopoietin 1 Product Details anti-Angiopoietin 1 Antibody Application Details Handling Images back to top ...
Angiopoietin 1 Polyclonal Antibody. Catalog Number. Pack Size. List Price*. Promo Price*. Quantity. ... Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for 12 months.. ... Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.. ...
  • The biological activity of the secreted human VEGF165 and Ang-1 was determined by human umbilical vein endothelial cells (HUVEC) proliferation assay, Thymidine [Hincorporation assay and capillary-like structure formation. (nus.edu.sg)
  • In this study, we present QHREDGS (glutamine-histidine-arginine-glutamic acid-aspartic acid-glycine-serine), a prosurvival peptide derived from angiopoietin-1, as a therapeutic candidate that targets re-epithelialization. (pnas.org)
  • The aim of this study was to investigate the clinical utility of whole blood angiopoietin (ANG) levels as biomarkers of disease severity in Plasmodium falciparum malaria. (beds.ac.uk)
  • These results suggest that whole blood ANG-1/2 levels are promising clinically informative biomarkers of disease severity in malarial syndromes. (beds.ac.uk)
  • Endothelial activation biomarkers including soluble intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and E-selectin, and plasma ANG-2 and angiopoietin-1 (ANG-1) were tested in stored plasma samples from 0, 6, and 12 months after ART initiation. (ac.ke)
  • CONCLUSIONS: Biomarkers of endothelial activation decreased after ART initiation in women with advanced HIV-1 infection. (ac.ke)
  • Soluble ICAM-1 and plasma ANG-2 levels represent potential biomarkers for adverse outcomes in advanced HIV-1 infection. (ac.ke)
  • We previously identified loss-of-function mutations in the angiopoietin (ANGPT) receptor TEK in families with PCG and showed that ANGPT/TEK signaling is essential for SC development. (jci.org)
  • In a murine mammary carcinoma model, Ang-1 is secreted and then bound to the extracellular matrix (7) where it is ideally situated to mediate cell-to-cell and cell-to-matrix interaction of capillaries (8,9) . (onlinejacc.org)
  • Construction of a 1.2-Mb sequence-ready contig of chromosome 11q13 encompassing the multiple endocrine neoplasia type 1 (MEN1) gene. (wikipedia.org)
  • OPN (also known as early T cell activation gene-1, or eta-1 ), is a secreted, highly acidic glycoprotein with pleiotropic effects ( 5 - 11 ). (rupress.org)
  • We investigated the role of Ang-1 in atherosclerosis-prone apolipoprotein-E (Apo-E) knockout mouse. (aston.ac.uk)
  • Ang-1 specifically increases circulating Gr1 + inflammatory monocytes and increases monocyte/macrophage retention in atherosclerotic plaques, thereby contributing to development of atherosclerosis. (aston.ac.uk)